|Other Names||Erbitux™, Anti EGFR, IMC-C225|
|Pharmaceutical Companies||Bristol Myers Squib, Merck Serono and Eli Lilly and Company|
|Inhibitor||Epidermal Growth Factor Receptor (EGFR) Inhibitor|
|Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.|
Due to cardiac arrest prevention, pretreatment with diphenhydramine 30-60 min. before administration is standard of care.